Granules India reported a 60% jump in net profit to ₹180 crore for the June quarter FY27, compared with ₹112.6 crore a year before, while revenue climbed 22% to ₹1,476 crore from ₹1,210 crore in Q1 FY26.
EBITDA surged 37.4% to ₹339 crore, a leap of ₹92.5 crore over the previous year, and the EBITDA margin expanded by 300 basis points to 23% from 20.3% a year earlier, nudging the company ahead of its sector peers.
In a filing on October 2, the company announced the incorporation of Triton Farmaceutica Do Brasil Ltda, a wholly owned subsidiary that will manufacture, promote and distribute pharmaceuticals in Brazil. The move required prior approval from the Reserve Bank of India via the automatic route and does not involve any promoter stake.
Executive Director Priyanka Chigurupati said the firm is poised to expand manufacturing in the U.S. if needed, noting that a U.S. tariff on imported generics would be mitigated by existing U.S. facilities and that the final tariff structure is expected to be lower than announced.
On the market, Granules India shares fell 2.6% to ₹824.50 on NSE, reflecting cautious sentiment ahead of the new Brazilian venture and looming U.S. trade dynamics.
Looking ahead, the company has not issued new guidance but expects to file its Q3 FY27 results next month, with analysts monitoring the Brazil launch for its impact on revenue diversification and margin expansion.